University of Ioannina
Διαταραχές του μεταβολισμού των αμινοξέων διακλαδισμένης αλυσίδας στο σακχαρώδη διαβήτη τύπου 2 και τα αυτοάνοσα νοσήματα του ήπατος
Abstract
dc:descriptionBranched chain amino acids (BCAAs), leucine, isoleucine and valine, are essential amino acids widely studied for their critical role in the regulation of protein synthesis (mTOR - mechanistic target of rapamycin - signaling pathway) and their emerging recognition as players in the regulation of energy metabolism, glucose homeostasis as well as normal function of immune system and brain. BCAA supplementation is primarily used as a beneficial nutritional intervention in chronic liver and kidney disease as well as muscle wasting disorders. However, the downregulated/upregulated levels of BCAAs in biological fluids and their defective catabolism in various tissues, mainly due to altered enzymatic activity of the first two enzymes in their catabolic pathway, BCAA aminotransferase (BCAT) and branched-chain a-keto acid dehydrogenase (BCKD), have been associated with many nutritional and disease states. The underlying mechanisms of impaired BCAA catabolism have been investigated in the pathogenesis of numerous pathological conditions such as inborn errors of metabolism, obesity and different types of diabetes, cardiovascular diseases, neurodegenerative disorders (Alzheimer's disease), cancer, kidney and liver disease. The recovery of the dysregulated BCAA catabolism may be associated with improved outcome and prevention of severe complications of the related disease. The aim of the present thesis was to investigate the pathophysiological/pathogenetic role of BCAAs and their catabolic intermediates, their possible prognostic and/or diagnostic value in Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus (GDM), Diabetic Nephropathy (DN) and Autoimmune Liver Diseases and treatment response. The study included 53 healthy controls, 50 patients with T2DM before and after treatment with dapagliflozin for 3 months, 22 patients with type 2 diabetes collected 3 years before the onset of DN, 62 women with GDM compared with 77 healthy pregnant women, 341 patients with Autoimmune Liver Diseases at diagnosis and after treatment and 101 patients with chronic viral hepatitis B and C. The metabolic profile of the biological fluids from the study groups was detected by Nuclear Magnetic Resonance (NMR) spectroscopy on a Bruker Avance DRX NMR 500MHz spectrometer (NMR Center, University of Ioannina) and on an Avance III 700 MHz spectrometer (University of Patra). In order to improved detection and quantification of low abundant metabolites in NMR spectroscopy, macromolecules (proteins and lipoproteins) were eliminated from serum/plasma samples by ultrafiltration. BCAAs and metabolites related to their catabolism were then identified and quantified from the analysis of 1HNMR spectrum. Based on the results of this thesis we conclude that, T2DM is characterized by a disturbed BCAA catabolism with main features: 1) the elevated levels of the three BCAAs and the α-keto acid of isoleucine, 3-methyl-2-oxovalerate in serum and urine 2) the accumulation of the valine catabolic intermediate 3-hydroxyisobutyrate and the reduction of the leucine catabolic products 2-oxoisocaproate and 3-hydroxyisovalerate in serum and 3) the increased urine concentration of the catabolic intermediates of isoleucine, 2-hydroxy-3-methylvalerate, of leucine, N-isovaleroylglycine and valine, 2-hydroxyisovalerate. Alterations in the levels of the above metabolites indicate reduced activity of the two main enzymes of the catabolic pathways of BCAAs and could be used as early biomarkers of impaired insulin sensitivity and onset of diabetes mellitus. Treatment of diabetic patients with the sodium glucose co-transporters-2 (SGLT-2) inhibitor dapagliflozin was followed by: 1) the decreased renal reabsorption of the three BCAAs may contribute to the regression of proximal tubular hypertrophy and 2) the elevated excretion of the catabolic products 2-hydroxyisovalerate, 2-hydroxy-3-methylvalerate and 3-hydroxyisovalerate as well as the decreased excretion of the two toxic catabolic intermediates, 3-methyl-2-oxovalerate and N-isovaleroylglycine. These changes possibly reflect an improvement in BCAA metabolism and may contribute to the renoprotective properties of dapagliflozin. The main alterations observed in patients 3 years before the diagnosis of DN were 1) the downregulated levels of the three BCAAs and 3-methyl-2-oxovalerate in the serum and urine which indicate an increase in BCKD dehydrogenase enzyme activity 2) the decreased serum levels of glutamate and 3) the reduced renal excretion of the catabolic intermediates, 2-hydroxyisovalerate, 2-hydroxy-3-methylvalerate, N-isovaleroylglycine, succinate, alanine and ketone bodies. The above metabolites, which are statistically significantly increased in T2DM and then decline statistically significantly 3 years before the diagnosis of nephropathy and could be prognostic biomarkers of DN.In GDM, compared to normal pregnancy, no changes in the levels of the three BCAAs per se were detected but of their catabolic intermediates. More specifically: 1) increased concentration of the leucine catabolic product 3-hydroxyisovalerate which is associated with increased ketogenesis and may be due to impaired function of the enzyme methylcrotonyl-CoA carboxylase possibly due to biotin deficiency, 2) elevated levels of the intermediate of valine degradation pathway 3-hydroxyisobutyrate, which may contribute to the accumulation of toxic lipid intermediates in muscles and lead to insulin resistance and 3) decreased levels of the isoleucine α-keto acid, 3-methyl-2-oxovalerate. These findings provide evidence that BCAA catabolism was affected in GDM but otherwise than in T2DM.In Autoimmune Liver Diseases, BCAAs were found to be mainly reduced. The lead causes are the increased catabolic rate because they are used 1) as precursors in the gluconeogenesis pathway, 2) as alternative ketogenic substrates in ketone bodies production (upregulated levels of ketone bodies), 3) in energy production (increased intermediates of the citric acid cycle) as well as 4) in ammonia detoxification pathways (increased levels of glutamate). In Autoimmune Hepatitis (AIH), the levels of isoleucine and the corresponding a-keto acid were found to be at normal levels, compared to the other two cholestatic autoimmune liver diseases (PBC & PSC), indicating these metabolites as candidate markers for the differential diagnosis of autoimmune liver diseases. Administration of immunosuppressive therapy in AIH patients was associated with improvement in the impaired catabolism of valine and leucine (reduction of 2-hydroxyisovalerate and 3-hydroxyisovalerate levels towards normal) following the improvement of liver fibrosis and biotin levels. Administration of ursodeoxycholic acid (UDCA) to PBC patients did not restore the reduced isoleucine levels but they were further decreased, indicating a metabolic profile closer to cirrhosis. Finally, in patients with PSC, treatment with ursodeoxycholic acid was associated with a statistically significant increase in leucine levels toward normal and an improvement in hepatic lipid metabolism. In conclusion, the levels of BCAAs and of their catabolic intermediates could be used as biomarkers of health and disease in clinical routine.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dimou, Aikaterini
- Δήμου, Αικατερίνη
Subjects
dc:subject × 16- Αμινοξέα διακλαδισμένης αλυσίδας
- Σακχαρώδης διαβήτης τύπου 2
- Αυτοάνοσα νοσήματα του ήπατος
- Φασματοσκοπία πυρηνικού μαγνητικού συντονισμού
- Μεταβολικά μονοπάτια
- Branched chain amino acids
- Type 2 diabetes
- Autoimmune liver diseases
- NMR spectroscopy
- Metabolic pathways
- Άλλες Ιατρικές Επιστήμες
- Ιατρική και Επιστήμες Υγείας
- Ιατρική έρευνα και Πειραματική ιατρική
- Other Medical Sciences
- Medical and Health Sciences
- Research and Experimental medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55058